Expert consensus on the clinical application of ormutivimab injection for use against the rabies virus
BACKGROUND: There are no local or international guidelines or consensus on the use of mAbs against the rabies virus.
RESEARCH DESIGN AND METHODS: An expert group in the field of rabies prevention and control formulated the consensus presented in this paper.
RESULTS: Class III exposed persons to rabies for the first time; Identify type II exposed persons with immune deficiency; those who are first exposed to Class II and re-exposed to Class III within 7 days. They can use ormutivimab injection after completing the PEP wound treatment. In the case of injection restrictions or a wound that is difficult to detect, it is recommended that the entire Ormutivimab dose be infiltrated close to the wound. For severe multi-wound bites, the recommended dosage of ormutivimab is 20 IU/kg. If the recommended dose cannot meet all of the wound infiltration requirements, appropriate dilution can be conducted at a dilution ratio of 3 ~ 5 times. If the requirements for infiltration cannot be met after dilution, it is recommended that the dosage be increased with caution (maximum dosage, 40 IU/kg). The use of Ormutivimab is safe and effective without any contraindications by all age groups.
CONCLUSIONS: This consensus standardizes clinical use of Ormutivimab, improves post-exposure prophylaxis of rabies in China, reduces infection rate.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Expert opinion on drug safety - (2023) vom: 12. Juli, Seite 1-8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Ruifeng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-rabies monoclonal antibody |
|---|
| Anmerkungen: |
Date Revised 12.07.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/14740338.2023.2233411 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359290264 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359290264 | ||
| 003 | DE-627 | ||
| 005 | 20231226080545.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14740338.2023.2233411 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1197.xml |
| 035 | |a (DE-627)NLM359290264 | ||
| 035 | |a (NLM)37427985 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Ruifeng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Expert consensus on the clinical application of ormutivimab injection for use against the rabies virus |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a BACKGROUND: There are no local or international guidelines or consensus on the use of mAbs against the rabies virus | ||
| 520 | |a RESEARCH DESIGN AND METHODS: An expert group in the field of rabies prevention and control formulated the consensus presented in this paper | ||
| 520 | |a RESULTS: Class III exposed persons to rabies for the first time; Identify type II exposed persons with immune deficiency; those who are first exposed to Class II and re-exposed to Class III within 7 days. They can use ormutivimab injection after completing the PEP wound treatment. In the case of injection restrictions or a wound that is difficult to detect, it is recommended that the entire Ormutivimab dose be infiltrated close to the wound. For severe multi-wound bites, the recommended dosage of ormutivimab is 20 IU/kg. If the recommended dose cannot meet all of the wound infiltration requirements, appropriate dilution can be conducted at a dilution ratio of 3 ~ 5 times. If the requirements for infiltration cannot be met after dilution, it is recommended that the dosage be increased with caution (maximum dosage, 40 IU/kg). The use of Ormutivimab is safe and effective without any contraindications by all age groups | ||
| 520 | |a CONCLUSIONS: This consensus standardizes clinical use of Ormutivimab, improves post-exposure prophylaxis of rabies in China, reduces infection rate | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-rabies monoclonal antibody | |
| 650 | 4 | |a clinical application | |
| 650 | 4 | |a consensus standardizes in China | |
| 650 | 4 | |a ormutivimab | |
| 650 | 4 | |a post-exposure prophylaxis | |
| 650 | 4 | |a rabies | |
| 700 | 1 | |a Li, Hu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Wuyang |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Hongbin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xiaomei |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Faliang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xiaoqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Shixiong |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Baigang |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Yishan |e verfasserin |4 aut | |
| 700 | 1 | |a Zuo, Yongbo |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Guanmu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xiangming |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug safety |d 2002 |g (2023) vom: 12. Juli, Seite 1-8 |w (DE-627)NLM126588422 |x 1744-764X |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:12 |g month:07 |g pages:1-8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14740338.2023.2233411 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 12 |c 07 |h 1-8 | ||